Drug    DrugBank | All Description Patterns💬 Info on mouse-over

No.	Drug (Description in trials)	DrugBank	KEGG DRUG	KEGG GENES	KEGG PATHWAY On map, Yellow: Drug target genes	Disease ID
1	Ana001xhcl (syntagon) or vexa-04 (patheon)	-	-	-	-	[1] 156 💬
2	Behavioral: clinical characteristics of ams patients	-	-	-	-	[1] 17 💬
3	Behavioral: pat sessions	-	-	-	-	[1]  6  💬
4	Behavioral: physical activity together for pwms and their cgs (pat-ms)	-	-	-	-	[1] 13 💬
5	Biil 284 bs, high dose, adult patients	-	-	-	-	[1] 299 💬
6	Biil 284 bs, high dose, pediatric patients	-	-	-	-	[1] 299 💬
7	Biil 284 bs, low dose, adult patients	-	-	-	-	[1] 299 💬
8	Biil 284 bs, low dose, pediatric patients	-	-	-	-	[1] 299 💬
9	Biil 284 bs, medium dose, adult patients	-	-	-	-	[1] 299 💬
10	Biil 284 bs, medium dose, pediatric patients	-	-	-	-	[1] 299 💬
11	Buprenorphine transdermal patch	Buprenorphine	[2] D00836, D07132 💬	[2] OPRK1, OPRM1 💬	[3] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction	[1] 46 💬
12	Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in als patients	-	-	-	-	[1]  2  💬
13	Cf patients with a g551d mutation and treated with ivacaftor	Ivacaftor	[1] D09916 💬	[1] CFTR 💬	[8] ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway	[1] 299 💬
14	Cryopreserved efs-ada lv transduced patient cd34+ cells	-	-	-	-	[1] 65 💬
15	Cryopreserved g2scid lentiviral vector transduced patient cd34+ cells	-	-	-	-	[1] 65 💬
16	Device: smartpill motility system & pillcam patency capsule	-	-	-	-	[1] 299 💬
17	Diagnostic test: blood drawing in patients with was	-	-	-	-	[1] 65 💬
18	Dietary supplement for pku patients	-	-	-	-	[1] 240 💬
19	Ef1as-ada lentiviral vector transduced patient cd34+ cells	-	-	-	-	[1] 65 💬
20	Etims (edc-fixed autologous pbmcs coupled with 7 immunodominant myelin peptides in ms patients)	-	-	-	-	[1] 13 💬
21	Ex vivo culture and transduction of the patient's autologous cd34+ hsc with lentivirus vector vsv-g pseudotyped cl20- 4i-ef1a-hyc-opt vector	-	-	-	-	[1] 65 💬
22	Exelon 4.6 mg/24 h transdermal patch	-	-	-	-	[1]  6  💬
23	Exelon 9.5 mg/24 h transdermal patch	-	-	-	-	[1]  6  💬
24	Exelon patch	-	-	-	-	[1]  6  💬
25	Exelon patch (rivastigmine transdermal system)	Rivastigmine	[2] D02558, D03822 💬	[1] ACHE 💬	[2] Cholinergic synapse, Glycerophospholipid metabolism	[1]  6  💬
26	Exelon path transdermal	-	-	-	-	[1]  6  💬
27	Fentanyl transdermal patch	Fentanyl	[2] D00320, D01399 💬	[1] OPRM1 💬	[3] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction	[1] 46 💬
28	Gamma-secretase/notch signalling pathway inhibitor ro4929097	-	-	-	-	[1] 74 💬
29	Golimumab 50 mg in patients <80 kg and golimumab 100 mg in patients >80 kg	Golimumab	[1] D04358 💬	[1] TNF 💬	[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway	[1] 97 💬
30	Growth hormone replacement therapy in growth hormone deficient patients only.	Somatotropin	[1] D02691 💬	[1] GHR 💬	[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway	[1] 78 💬
31	Hp-3000 (ropinirole hydrochloride patch)	Ropinirole	[2] D00784, D08489 💬	[3] DRD2, DRD3, DRD4 💬	[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway	[1]  6  💬
32	Hp-3000(ropinirole hydrochloride patch)	Ropinirole	[2] D00784, D08489 💬	[3] DRD2, DRD3, DRD4 💬	[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway	[1]  6  💬
33	Intervention for incipient patients at low risk of disease progression	-	-	-	-	[1] 66 💬
34	Intervention for patients at high risk of disease progression	-	-	-	-	[1] 66 💬
35	Lidocaine patch 5%	Lidocaine	[3] D00358, D02086, D08127 💬	[5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬	[3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction	[1] 13 💬
36	Long term follow up in all patients who received sar422459 in previous study tdu13583	-	-	-	-	[1] 301 💬
37	Loxoprofen sodium hydrogel patch	Loxoprofen	[1] D08149 💬	[2] PTGS1, PTGS2 💬	[23] Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway	[1] 271 💬
38	Neupro 2 mg/24 h transdermal patch	-	-	-	-	[1]  6  💬
39	Neupro 2mg/24 h transdermal patch	-	-	-	-	[1]  6  💬
40	Neupro 2mg/24h transdermal patch	-	-	-	-	[1]  6  💬
41	Neupro 4 mg/24 h transdermal patch	-	-	-	-	[1]  6  💬
42	Neupro 4mg/24 h transdermal patch	-	-	-	-	[1]  6  💬
43	Neupro 4mg/24h transdermal patch	-	-	-	-	[1]  6  💬
44	Neupro 4mg/24hr transdermal patch	-	-	-	-	[1]  6  💬
45	Neupro 6 mg/24 h transdermal patch	-	-	-	-	[1]  6  💬
46	Neupro 6mg/24 h transdermal patch	-	-	-	-	[1]  6  💬
47	Neupro 6mg/24h transdermal patch	-	-	-	-	[1]  6  💬
48	Neupro 8 mg/24 h transdermal patch	-	-	-	-	[1]  6  💬
49	Neupro 8mg/24h transdermal patch	-	-	-	-	[1]  6  💬
50	Nicotine patch	Nicotine	[3] D03365, D05156, D05157 💬	[16] CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬	[7] Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases	[2]  6 , 84 💬
51	Nicotine transdermal patch	Nicotine	[3] D03365, D05156, D05157 💬	[16] CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬	[7] Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases	[1]  6  💬
52	Observational study with patients treated with tracleer, ventavis, veletri, opsumit and/or uptravi	-	-	-	-	[1] 86 💬
53	Other: histone acetylation profiles of cells of srt patients with crebbp mutations	-	-	-	-	[1] 102 💬
54	Other: neupro 4 mg / 24 hr. transdermal patch	-	-	-	-	[1]  6  💬
55	Other: observation of ocrelizumab as treatment in rrms patients	Ocrelizumab	[1] D05218 💬	[1] MS4A1 💬	[1] Hematopoietic cell lineage	[1] 13 💬
56	Other: the patients' parents have to complete the vineland ii adaptive behavior scales scoring, the sleep disturbance scale for children (sdsc) and horne & ostberg circadian typology questionnaire	-	-	-	-	[1] 149 💬
57	Other: transthoracic echocardiography at rest, during plr, hg and cpx (including blood gas analysis in both groups). additionally fallot patients will undergo routine blood testings.	-	-	-	-	[1] 215 💬
58	Oxycodone by patient-controlled analgesia (pca)	Oxycodone	[3] D03783, D05312, D05462 💬	[3] OPRD1, OPRK1, OPRM1 💬	[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway	[1] 46 💬
59	Pat	-	-	-	-	[3]  6 , 13, 160 💬
60	Pat-001, 0.1%	-	-	-	-	[1] 160 💬
61	Pat-001, 0.2%	-	-	-	-	[1] 160 💬
62	Patient current care	-	-	-	-	[1] 46 💬
63	Patient treated with dmard	-	-	-	-	[1] 46 💬
64	Patients will be randomized to receive ehp-101	-	-	-	-	[1] 51 💬
65	Patients' existing non-steroidal anti-inflammatory drug (nsaid) at approved doses	-	-	-	-	[1] 46 💬
66	Pd patients h&y=1.5-2 medications off	-	-	-	-	[1]  6  💬
67	Pd patients h&y=1.5-2 medications on	-	-	-	-	[1]  6  💬
68	Pd patients h&y=3 medications off	-	-	-	-	[1]  6  💬
69	Pd patients h&y=3 medications on	-	-	-	-	[1]  6  💬
70	Procedure: skin biopsy for the primary fibroblast culture and a 15 ml blood sample (3 unnamed samples of 5ml) in each of the 4 srt patients included.	-	-	-	-	[1] 102 💬
71	Procedure: speech pathology evaluation	-	-	-	-	[1] 78 💬
72	Procedure: tof repair with trans-annular patch vs preservation of pv	-	-	-	-	[1] 215 💬
73	Procedure: use of an electronic data capture system by patients and physicians to assess patient-physician interactions & therapeutic decisions & outcomes in ra subjects.	Bifenthrin	-	-	-	[1] 46 💬
74	Rituximab, observational study amon patients with active ra	Rituximab	[1] D02994 💬	[1] MS4A1 💬	[1] Hematopoietic cell lineage	[1] 46 💬
75	Rivastigmin luye transdermal patches - 4.6mg/24h	-	-	-	-	[1]  6  💬
76	Rivastigmine luye transdermal patch- 9.5mg/24h	Rivastigmine	[2] D02558, D03822 💬	[1] ACHE 💬	[2] Cholinergic synapse, Glycerophospholipid metabolism	[1]  6  💬
77	Rivastigmine patch 9.5 cm2	Rivastigmine	[2] D02558, D03822 💬	[1] ACHE 💬	[2] Cholinergic synapse, Glycerophospholipid metabolism	[1]  6  💬
78	Rivastigmine transdermal patch	Rivastigmine	[2] D02558, D03822 💬	[1] ACHE 💬	[2] Cholinergic synapse, Glycerophospholipid metabolism	[2]  6 , 13 💬
79	Rotigotine transdermal patch	Rotigotine	[1] D05768 💬	[1] DRD2 💬	[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway	[1]  6  💬
80	Rotigotine transdermal patch 2mg/24h(10cm2)	Rotigotine	[1] D05768 💬	[1] DRD2 💬	[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway	[1]  6  💬
81	Rotigotine transdermal patch 4mg/24h (20cm2)	Rotigotine	[1] D05768 💬	[1] DRD2 💬	[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway	[1]  6  💬
82	Rotigotine transdermal patch 6mg/24h (30cm2)	Rotigotine	[1] D05768 💬	[1] DRD2 💬	[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway	[1]  6  💬
83	Rotigotine transdermal patch 8mg/24h (40cm2)	Rotigotine	[1] D05768 💬	[1] DRD2 💬	[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway	[1]  6  💬
84	Routine transdermal oestrogen patch	-	-	-	-	[1] 78 💬
85	The effectiveness of xeljanz in rheumatoid arthritis patients	-	-	-	-	[1] 46 💬
86	Tnf-blockers suspension in patients with rheumatoid arthritis	-	-	-	-	[1] 46 💬
87	Transduced patient cd34+ cells	-	-	-	-	[1] 65 💬
88	Treat with lansoprazole 30 mg bid for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms	Lansoprazole	[1] D00355 💬	[2] ATP4A, ATP4B 💬	[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation	[1] 98 💬

Back to top